LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3257 | 5578 | 0.5838 | 0.2351 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3478 | 5578 | 0.6235 | 0.3079 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5783 | 5578 | 1.0366 | 1.0673 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5607 | 5578 | 1.0052 | 1.0096 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2170 | 5578 | 0.3890 | -0.1229 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5508 | 5578 | 0.9875 | 0.9769 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2093 | 5578 | 0.3753 | -0.1482 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3325 | 5578 | 0.5960 | 0.2575 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1576 | 5578 | 0.2825 | -0.3188 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1722 | 5578 | 0.3087 | -0.2705 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1167 | 5578 | 0.2093 | -0.4534 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1462 | 5578 | 0.2621 | -0.3562 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5595 | 5578 | 1.0029 | 1.0054 |
| SK-BR-3 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1036 | 5578 | 0.1857 | -0.4967 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4369 | 5578 | 0.7832 | 0.6016 |
| SK-BR-3 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1433 | 5578 | 0.2569 | -0.3658 |
| SK-BR-3 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2049 | 5578 | 0.3674 | -0.1628 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 4038 | 5578 | 0.7240 | 0.4926 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5619 | 5578 | 1.0073 | 1.0134 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1926 | 5578 | 0.3453 | -0.2033 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3181 | 5578 | 0.5702 | 0.2101 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2167 | 5578 | 0.3884 | -0.1240 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3065 | 5578 | 0.5494 | 0.1718 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5453 | 5578 | 0.9776 | 0.9588 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4635 | 5578 | 0.8309 | 0.6892 |